8-KShareholder MattersExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (May 21, 2021)

Filed May 21, 2021For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) held its 2021 Annual Meeting of Stockholders on May 18, 2021, where key governance and operational matters were put to a vote. The company reported that as of March 29, 2021, there were 117,320,127 shares of common stock outstanding. Of primary interest to investors, the stockholders overwhelmingly re-elected four Class II directors, ensuring continuity in leadership. Furthermore, the compensation of the company's named executive officers was approved in a non-binding advisory vote, and the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2021 was ratified. These outcomes suggest strong stockholder confidence in the current board and the company's financial oversight.

Key Highlights

  • 1Four Class II directors (Dennis A. Ausiello, Olivier Brandicourt, Marsha H. Fanucci, David E.I. Pyott) were re-elected with significant majority support, with terms extending to the 2024 annual meeting.
  • 2The compensation of Alnylam's named executive officers received approval in a non-binding advisory vote, indicating shareholder support for executive pay structures.
  • 3PricewaterhouseCoopers LLP was ratified as the company's independent auditor for the fiscal year ending December 31, 2021, by a substantial margin.
  • 4The company had 117,320,127 shares of common stock issued and outstanding as of the record date (March 29, 2021) for the meeting.
  • 5Broker non-votes were present for the director elections and executive compensation vote, but absent for the auditor ratification, suggesting strong shareholder participation in the latter.
  • 6The director re-elections saw very high 'Votes For' percentages, with generally low 'Votes Against' and 'Abstentions'.

Frequently Asked Questions

The main outcomes included the re-election of four Class II directors, the approval of named executive officer compensation in an advisory vote, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2021. All these proposals passed with significant stockholder support.

Stockholders overwhelmingly re-elected all four nominated Class II directors: Dennis A. Ausiello, M.D., Olivier Brandicourt, M.D., Marsha H. Fanucci, and David E.I. Pyott. The 'Votes For' vastly outnumbered 'Votes Against' and 'Abstentions' for each nominee.

Yes, the compensation of Alnylam's named executive officers was approved in a non-binding advisory vote, with 81,382,437 votes in favor and 20,146,079 votes against.

PricewaterhouseCoopers LLP was ratified by the stockholders as Alnylam's independent auditor for the fiscal year ending December 31, 2021. This ratification received broad support.